Envue Medical Q2 FY26 net loss widens 23% to $4.9 million; revenue falls 51.6% to $239,000 - FEED News | RalliesEnvue Medical Q2 FY26 net loss widens 23% to $4.9 million; revenue falls 51.6% to $239,000
F
FEED• Second-quarter results
- Envue Medical posted a net loss of USD 4.9 million for the quarter ended June 30, 2026, widening 23%.
- Revenue fell 51.6% to USD 239,000, due to a PainShield/UroShield production halt tied to the war in Israel.
- Gross loss widened to USD 266,000, on USD 140,000 of ENvue-merger amortization, discounted ENvue system sales, and a USD 41,000 inventory write-down.
- Selling and marketing expenses climbed 78% to USD 1.2 million, driven by ENvue commercialization and UroShield expansion into the U.K.
Liquidity and going concern
- Cash and cash equivalents totaled USD 1.08 million; management flagged substantial doubt about going concern over the next 12 months.
